Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint...

Area of Science:

• Cancer immunology
• Molecular oncology
• Immunotherapy

Background:

• The antiapoptotic protein BCL2 is crucial for lymphocyte development and immune responses, and is involved in cancer cell survival.
• The role of BCL2 in antitumor immunity is not well understood.
• Immune checkpoint inhibitors (ICIs) are a key cancer therapy, but their efficacy can be limited.

Purpose of the Study:

• To investigate if venetoclax, a selective BCL2 inhibitor, can enhance the antitumor activity of ICIs.
• To explore the impact of venetoclax on T cell populations within the tumor microenvironment.
• To assess the safety and efficacy of combining venetoclax with ICIs in preclinical cancer models.

Main Methods:

• Utilized mouse syngeneic tumor models to evaluate combination therapy.
• Assessed changes in immune cell populations, specifically PD-1+ T effector memory cells.
• Performed in vitro studies using human T cells to evaluate venetoclax's effect on T cell function and activation.

Main Results:

• Venetoclax significantly augmented the antitumor efficacy of ICIs in preclinical models.
• Combination therapy led to an increase in PD-1+ T effector memory cells.
• Venetoclax did not impair human T cell function in vitro and did not antagonize anti-PD-1 activity.

Conclusions:

• BCL2 inhibition with venetoclax can enhance the effectiveness of immune checkpoint inhibitors.
• The combination therapy shows promise for improving anticancer immunotherapy by modulating T cell responses.
• Further clinical evaluation of venetoclax in combination with ICIs for cancer treatment is warranted.